| - |
Nab-paclitaxel |
Abraxane® |
In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas. |
Assessment Process Complete |
5th September 2014 |
 |
| - |
Nalmefene |
Selincro® |
Is indicated for the reduction of alcohol consumption in those aged ≥18 years with alcohol dependence, who do not require immediate detoxification. |
Assessment Process Complete |
8th April 2014 |
|
| - |
Naloxegel |
Moventig® |
Is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). |
Rapid Review Complete |
13th April 2015 |
|
| 20019 |
Naloxone |
Nyxoid® |
Intranasal spray is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid® is indicated in adults and adolescents aged 14 years and over. Nyxoid® is not a substitute for emergency medical care. |
Rapid Review Complete |
12th May 2020 |
|
| - |
Naltrexone / bupropion |
Mysimba® |
Is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities. |
Assessment Process Complete |
9th May 2018 |
|
| - |
Natalizumab |
Tysabri® |
For the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated. |
Full HTA Assessment |
27th April 2007 |
|
| - |
Nepafenac |
Nevanac® |
For the prevention and treatment of postoperative pain and inflammation associated with cataract surgery. |
Rapid Review Complete |
27th June 2011 |
|
| 19057 |
Neratinib |
Nerlynx® |
For the extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago. |
Assessment Process Complete |
12th May 2021 |
|
| 23076 |
Netarsudil-latanoprost |
Roclanda® |
Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient intraocular pressure reduction. |
Rapid Review Complete |
5th June 2024 |
|
| - |
Netupitant/palonosetron |
Akynzeo® |
For the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. |
Rapid Review Complete |
13th October 2015 |
|
| - |
Nilotinib CML resistant/intolerant to imatinib |
Tasigna® |
For the treatment of chronic phase CML. |
Full HTA Assessment |
25th February 2008 |
|
| - |
Nilotinib |
Tasigna® |
For the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML. |
Rapid Review Complete |
22nd October 2010 |
|
| - |
Nintedanib |
Ofev® |
Indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF). |
Assessment Process Complete |
22nd February 2016 |
|
| 20034 |
Nintedanib |
Ofev® |
For the treatment of other progressive, chronic fibrosing interstitial lung diseases (PF-ILD) in adults. |
Assessment Process Complete |
24th June 2021 |
|
| - |
Nintedanib |
Vargatef® |
Is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. |
Assessment Process Complete |
25th March 2016 |
|
| 21004 |
Niraparib |
Zejula® |
Is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
NCPE Assessment Process Complete |
26th September 2022 |
|
| - |
Niraparib |
Zejula® |
Is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. |
Assessment Process Complete |
14th August 2019 |
|
| 23032 |
Niraparib in combination with abiraterone acetate |
Akeega® |
Niraparib in combination with abiraterone acetate and prednisone/prednisolone is indicated for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated. |
Rapid Review Complete |
20th October 2023 |
|
| 22014 |
Nirmatrelvir/Ritonavir |
Paxlovid® |
Is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. |
NCPE Assessment Process Complete |
20th June 2024 |
|
| - |
Nivolumab |
Opdivo® |
As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. |
Assessment Process Complete |
17th October 2019 |
|
| 20057 |
Nivolumab |
Opdivo® |
As monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy. |
Rapid Review Complete |
13th January 2021 |
|
| 21043 |
Nivolumab |
Opdivo® |
Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. |
NCPE Assessment Process Complete |
20th October 2023 |
|
| 21049 |
Nivolumab |
Opdivo® |
Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5. |
NCPE Assessment Process Complete |
11th July 2023 |
|
| - |
Nivolumab |
Opdivo® |
Is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults |
Assessment Process Complete |
28th March 2017 |
|
| - |
Nivolumab |
Opdivo® |
As monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin. |
Rapid Review Complete |
18th January 2017 |
|
| - |
Nivolumab |
Opdivo® |
For the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy. |
Rapid Review Complete |
30th May 2017 |
|
| - |
Nivolumab |
Opdivo® |
Is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma. Rapid Review |
Assessment Process Complete |
18th March 2016 |
|
| 22046 |
Nivolumab |
Opdivo® |
Is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC. |
NCPE Assessment Process Complete |
21st February 2024 |
|
| - |
Nivolumab |
Opdivo® |
Is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy. |
Assessment Process Complete |
12th October 2016 |
|
| - |
Nivolumab |
Opdivo® |
Opdivo® is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults. |
Assessment Process Complete |
10th March 2016 |
|
| 22045 |
Nivolumab |
Opdivo® |
Nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell PD-L1 (programmed death ligand 1) expression ≥1%. |
Rapid Review Complete |
20th October 2023 |
|
| - |
Nivolumab |
Opdivo® |
As monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. |
Assessment Process Complete |
12th September 2018 |
|
| - |
Nivolumab |
Opdivo® |
Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC) for RCC. |
Assessment Process Complete |
8th January 2020 |
|
| 21023 |
Nivolumab |
Opdivo® |
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 23050 |
Nivolumab |
Opdivo® |
In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%. |
Rapid Review Complete |
5th June 2024 |
|
| 21018 |
Nivolumab in combination with ipilimumab |
Opdivo® plus Yervoy® |
Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. |
NCPE Assessment Process Complete |
7th September 2022 |
|
| - |
Nivolumab plus ipilimumab |
Opdivo® plus Yervoy® |
For the treatment of advanced melanoma. |
Rapid Review Complete |
9th November 2016 |
|
| 21014 |
Nivolumab plus ipilimumab plus platinum-doublet chemotherapy |
Opdivo® plus Yervoy® |
For the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumours have no sensitising EGFR mutation or ALK translocation. |
Rapid Review Complete |
30th April 2021 |
|
| 24009 |
Nivolumab+relatlimab |
Opdualag® |
Nivolumab+relatlimab (Opdualag® ) is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. |
Rapid Review Complete |
16th April 2024 |
|
| - |
Nomegestrol acetate/estradiol |
Zoely® |
Nomegestrol acetate/estradiol (Zoely®) oral contraception |
Rapid Review Complete |
3rd January 2012 |
|
| 20044 |
Nusinersen |
Spinraza® |
For the treatment of 5q spinal muscular atrophy (SMA) in adults patients (>18 years). |
Rapid Review Complete |
29th October 2020 |
|
| - |
Nusinersen |
Spinraza® |
Is indicated for the treatment of 5q spinal muscular atrophy (SMA) |
Assessment Process Complete |
19th December 2017 |
|
